The stock of Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has decreased by -8.74 when compared to last closing price of 243.27. Despite this, the company has experienced a -15.31% fall in its stock price over the last five trading sessions. zacks.com reported 2025-04-10 that Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is It Worth Investing in Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Right Now?
Company’s 36-month beta value is 0.19.Analysts have differing opinions on the stock, with 12 analysts rating it as a “buy,” 12 as “overweight,” 8 as “hold,” and 1 as “sell.”
The public float for ALNY is 124.35M, and currently, short sellers hold a 2.40% ratio of that floaft. The average trading volume of ALNY on April 10, 2025 was 872.57K shares.
ALNY’s Market Performance
The stock of Alnylam Pharmaceuticals Inc (ALNY) has seen a -15.31% decrease in the past week, with a -8.42% drop in the past month, and a -7.70% fall in the past quarter. The volatility ratio for the week is 10.64%, and the volatility levels for the past 30 days are at 6.30% for ALNY. The simple moving average for the last 20 days is -13.32% for ALNY stock, with a simple moving average of -14.33% for the last 200 days.
Analysts’ Opinion of ALNY
Many brokerage firms have already submitted their reports for ALNY stocks, with Redburn Atlantic repeating the rating for ALNY by listing it as a “Buy.” The predicted price for ALNY in the upcoming period, according to Redburn Atlantic is $353 based on the research report published on March 31, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see ALNY reach a price target of $328, previously predicting the price at $280. The rating they have provided for ALNY stocks is “Overweight” according to the report published on March 24th, 2025.
ALNY Trading at -13.18% from the 50-Day Moving Average
After a stumble in the market that brought ALNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.06% of loss for the given period.
Volatility was left at 6.30%, however, over the last 30 days, the volatility rate increased by 10.64%, as shares sank -8.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.85% lower at present.
During the last 5 trading sessions, ALNY fell by -15.19%, which changed the moving average for the period of 200-days by -0.26% in comparison to the 20-day moving average, which settled at $256.16. In addition, Alnylam Pharmaceuticals Inc saw -5.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALNY starting from Garg Pushkal, who sale 5,445 shares at the price of $300.00 back on Mar 24 ’25. After this action, Garg Pushkal now owns 20,221 shares of Alnylam Pharmaceuticals Inc, valued at $1,633,500 using the latest closing price.
Garg Pushkal, the CMO & EVP Dev & Med Affairs of Alnylam Pharmaceuticals Inc, sale 4,321 shares at $285.00 during a trade that took place back on Mar 21 ’25, which means that Garg Pushkal is holding 20,221 shares at $1,231,485 based on the most recent closing price.
Stock Fundamentals for ALNY
Current profitability levels for the company are sitting at:
- -0.08 for the present operating margin
- 0.86 for the gross margin
The net margin for Alnylam Pharmaceuticals Inc stands at -0.12. The total capital return value is set at -0.06.
Based on Alnylam Pharmaceuticals Inc (ALNY), the company’s capital structure generated 0.95 points at debt to capital in total, while cash flow to debt ratio is standing at -0.01. The debt to equity ratio resting at 19.32. The interest coverage ratio of the stock is -1.25.
Currently, EBITDA for the company is -178.85 million with net debt to EBITDA at -1.71. When we switch over and look at the enterprise to sales, we see a ratio of 12.98. The receivables turnover for the company is 5.55for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.78.
Conclusion
In a nutshell, Alnylam Pharmaceuticals Inc (ALNY) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
